Claro has a comprehensive and expanding intellectual property portfolio including patents, exclusive licenses, proprietary know-how and optical profile databases. The IP strategy encompasses enhancements to and evolution of the core technology, hardware, software, and the continuous generation of laboratory and field data. These protections include new patents for expanded multiwavelength analysis and hardware systems, and specific product applications for blood culturing, blood analysis protein analysis and urinalysis. These new patents will be owned by Claro.
Claro is advancing a strategic plan for patent filings that is aligned with the Company’s business plan. This effort is focused on the generation of additional disclosures and patents pertaining to the Company’s proprietary technology focusing on two important areas: the core SpectraWave system and market-specific applications. As an example of Claro’s success in filing for application-specific patents, the Company generated six additional biomedical-related disclosures pertaining to blood culture analysis in 2009. In 2011, Claro is preparing to file new disclosures and patents related to protein analysis and our advances in whole blood and hemodialysis applications. This important and ongoing effort not only secures Claro’s competitive position, it also further reinforces the proprietary expertise resident within the Company.